Celularity is a clinical stage biotechnology company leading the next evolution in cellular medicine by developing off-the-shelf placental-derived allogeneic cell therapies, including unmodified NK cells, genetically-modified NK cells, T cells engineered with a CAR (CAR T-cells), and mesenchymal-like adherent stromal cells (ASCs) targeting indications across cancer, infectious, and degenerative diseases. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it will be able to develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies.

Madison, WI, USA

Florham Park, NJ, USA

Warren, OH, USA

Celularity

Therapeutics

S32 is a venture capital fund founded by Bill Maris.

Section 32, LLC

Tell us about your professional DNA to get discovered by any company in our network with opportunities relevant to your career goals.

Leverage our network to build your career.

#### Welcome!

Thank you for joining Section 32 Network!

To help us best support you in your search, please take a few minutes to tell us about what you are looking for in your next role. We’ll use this information to connect you to relevant opportunities in the Section 32 network as they come up.

You can always update this information later.

Welcome to the Section 32 talent network

As our companies grow, they look to us to help them find the best talent.

Signal that you'd be interested in working with a Section 32 company to help us put the right opportunities at great companies on your radar. The choice to pursue a new career move is then up to you.

Your professional information is now visible to our team and companies in our network.
We will be in touch when we find a great opportunity for you at one of our companies.

Thanks for signing up

As our companies grow, they look to us to help them find the best talent.
Signal that you'd be interested in working with a Section 32 company to help us put the right opportunities at great companies on your radar. The choice to pursue a new career move is then up to you.